Key Points

  • U2 exhibited low rates of immune-mediated toxicities associated with other PI3K-δ, including diarrhea, colitis, pneumonia, and hepatic toxicity.

  • This combination had promising preliminary activity across a broad range of B-cell malignancies, including a 17% complete response rate.

Abstract

Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies. The safety of the next-generation compounds umbralisib, a PI3K-δ inhibitor, plus ublituximab, an anti-CD20 monoclonal antibody (combination referred to as U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study. Phase 1 dose escalation was performed with a 3 + 3 design to establish the maximum tolerated dose. In this portion, ublituximab was given intravenously (NHL, 900 mg; CLL, 600 or 900 mg) for 12 cycles. Umbralisib was given orally once daily at 800 or 1200 mg (initial formulation) or 400 to 1200 mg (micronized formulation) in the phase 1 dose escalation portion, and at 800 to 1200 mg in the phase 1b portion until progression, toxicity, or study removal. The maximum tolerated dose was not reached in either the CLL or NHL cohort, and only 1 dose-limiting toxicity was observed. U2 had low instances of grade 3 or higher diarrhea (8%), pneumonia (8%), or hepatic toxicity (4%). Treatment discontinuation due to adverse events occurred in 13% of patients, and umbralisib dose reductions occurred in 15% of patients. The overall response rate for all patients was 46% with 17% complete responses. The median duration of response was 20 months (95% confidence interval, 11.3-not reached). U2 was well tolerated, and no new safety signals were observed over single-agent umbralisib. Preliminary efficacy with this combination is promising and warrants further investigation. This study was registered at www.clinicaltrials.gov as #NCT02006485.

REFERENCES

REFERENCES
1.
Salles
G
,
Barrett
M
,
Foà
R
, et al
.
Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
.
Adv Ther
.
2017
;
34
(
10
):
2232
-
2273
.
2.
Lannutti
BJ
,
Meadows
SA
,
Herman
SE
, et al
.
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
.
Blood
.
2011
;
117
(
2
):
591
-
594
.
3.
Okkenhaug
K
.
Signaling by the phosphoinositide 3-kinase family in immune cells
.
Annu Rev Immunol
.
2013
;
31
(
1
):
675
-
704
.
4.
Ringshausen
I
,
Schneller
F
,
Bogner
C
, et al
.
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta
.
Blood
.
2002
;
100
(
10
):
3741
-
3748
.
5.
Woyach
JA
,
Johnson
AJ
,
Byrd
JC
.
The B-cell receptor signaling pathway as a therapeutic target in CLL
.
Blood
.
2012
;
120
(
6
):
1175
-
1184
.
6.
Furman
RR
,
Sharman
JP
,
Coutre
SE
, et al
.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
.
N Engl J Med
.
2014
;
370
(
11
):
997
-
1007
.
7.
Dreyling
M
,
Santoro
A
,
Mollica
L
, et al
.
Updated safety and efficacy from the copanlisib CHRONOS-1 trial in patients with relapsed or refractory indolent B-cell lymphoma: low incidence of late-onset severe toxicities [abstract]
.
Blood
.
2017
;
130
(
suppl 1
).
Abstract 2777
.
8.
Flinn
IW
,
Hillmen
P
,
Montillo
M
, et al
.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
.
Blood
.
2018
;
132
(
23
):
2446
-
2455
.
9.
Le Garff-Tavernier
M
,
Herbi
L
,
de Romeuf
C
, et al
.
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
.
Leukemia
.
2014
;
28
(
1
):
230
-
233
.
10.
Burris
HA
III
,
Flinn
IW
,
Patel
MR
, et al
.
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
.
Lancet Oncol
.
2018
;
19
(
4
):
486
-
496
.
11.
Deng
C
,
Sportelli
P
,
Rodriguez
R
, et al
.
Novel PI3K inhibitors demonstrated marked cytotoxicity in T cell lymphoma models, caused apoptosis and were synergistic with a novel anti-CD20 monoclonal antibody ublituximab in B cell lymphoma models
.
Blood
.
2012
;
120
(
21
):
3725
-
3725
.
12.
Sawas
A
,
Farber
CM
,
Schreeder
MT
, et al
.
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
.
Br J Haematol
.
2017
;
177
(
2
):
243
-
253
.
13.
Davids
MS
,
Flinn
IW
,
Mato
AR
, et al
. Long term integrated safety analysis of umbralisib (TGR-1202), a PI3-delta/CK1-epsilon inhibitor with a differentiated safety profile, in patients with relapsed/refractory lymphoid malignancies.
Paper presented at: Congress of the European Hematology Association (EHA)
.
14.
Davids
MS
,
Kim
HT
,
Nicotra
A
, et al
.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
.
Lancet Haematol
.
2019
;
6
(
1
):
e38
-
e47
.
15.
Sharman
JP
,
Farber
CM
,
Mahadevan
D
, et al
.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
.
Br J Haematol
.
2017
;
176
(
3
):
412
-
420
.
16.
Nastoupil
LJ
,
Lunning
MA
,
Vose
JM
, et al
.
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
.
Lancet Haematol
.
2019
;
6
(
2
):
e100
-
e109
.
17.
Flinn
IW
,
Kahl
BS
,
Leonard
JP
, et al
.
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
.
Blood
.
2014
;
123
(
22
):
3406
-
3413
.
18.
Gopal
AK
,
Kahl
BS
,
de Vos
S
, et al
.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
.
N Engl J Med
.
2014
;
370
(
11
):
1008
-
1018
.
19.
de Weerdt
I
,
Koopmans
SM
,
Kater
AP
,
van Gelder
M
.
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
.
Haematologica
.
2017
;
102
(
10
):
1629
-
1639
.
20.
Hallek
M
,
Cheson
BD
,
Catovsky
D
, et al;
International Workshop on Chronic Lymphocytic Leukemia
.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
.
Blood
.
2008
;
111
(
12
):
5446
-
5456
.
21.
Cheson
BD
,
Pfistner
B
,
Juweid
ME
, et al;
International Harmonization Project on Lymphoma
.
Revised response criteria for malignant lymphoma
.
J Clin Oncol
.
2007
;
25
(
5
):
579
-
586
.
22.
Hans
CP
,
Weisenburger
DD
,
Greiner
TC
, et al
.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
.
Blood
.
2004
;
103
(
1
):
275
-
282
.
23.
Burris
HA
,
Patel
MR
,
Fenske
TS
, et al
.
Clinical activity and safety profile of TGR-1202, a novel once daily PI3Kδ inhibitor, in patients with CLL and B-cell lymphoma [abstract]
.
J Clin Oncol
.
2015
;
33
(
suppl 15
).
Abstract 7069
.
24.
Cheah
CY
,
Fowler
NH
.
Idelalisib in the management of lymphoma
.
Blood
.
2016
;
128
(
3
):
331
-
336
.
25.
Flinn
IW
,
Cherry
M
,
Maris
M
,
Matous
JV
,
Berdeja
JG
,
Patel
MR
.
Combination trial of duvelisib (IPI-145) with bendamustine, rituximab, or bendamustine/rituximab in patients with lymphoma or chronic lymphocytic leukemia [abstract]
.
Blood
.
2015
;
126
(
23
).
Abstract 3928
.
You do not currently have access to this content.

Comments

0 Comments